Company Description
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis.
Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.
The company’s product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms.
It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand.
The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018.
Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 2005 |
| IPO Date | May 1, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 30 |
| CEO | Maria Palasis |
Contact Details
Address: 480 Arsenal Way Watertown, Massachusetts 02472 United States | |
| Phone | 617 393 4600 |
| Website | lyratherapeutics.com |
Stock Details
| Ticker Symbol | LYRA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001327273 |
| CUSIP Number | 55234L105 |
| ISIN Number | US55234L1052 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Maria Palasis Ph.D. | Chief Executive Officer, President and Chairman |
| Jason Cavalier | Chief Financial Officer, Treasurer and Secretary |
| Dr. Carmichael S. Roberts Jr., Ph.D. | Co-Founder |
| Ronan P. O'Brien J.D. | Chief Legal Officer |
| Vineeta Belanger Ph.D. | Senior Vice President of Clinical Affairs |
| Dr. Robert Kern M.D. | Chief Clinical Advisor |
| Gloria Cosgrove | Senior Vice President of Quality |
| Allison Nance | Senior Vice President of Regulatory Affairs |
| Dr. Elazer R. Edelman FACC, M.D., Ph.D. | Vice President of Finance and Risk |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 22, 2025 | 8-K | Current Report |
| Aug 14, 2025 | SCHEDULE 13D/A | Filing |
| Aug 12, 2025 | 10-Q | Quarterly Report |
| Aug 12, 2025 | 8-K | Current Report |
| Aug 1, 2025 | 8-K | Current Report |
| Jul 31, 2025 | 424B3 | Prospectus |
| Jul 30, 2025 | EFFECT | Notice of Effectiveness |
| Jul 28, 2025 | UPLOAD | Filing |
| Jul 22, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jul 10, 2025 | 144 | Filing |